Publications

Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020 by Duncan LR, Hamed KA, Smart JI, Pfaller MA, Flamm RK, Mendes RE published in Diagn. Microbiol. Infect. Dis. 2022; 103: 115713.

Selection of the appropriate avibactam concentration for use with ceftibuten in broth microdilution susceptibility testing by Sader HS, Lindley J, Deshpande LM, Doyle T, Castanheria M. in Diagn. Microbiol. Infect. Dis. 2002; 103 (2) 115673.

Evaluation of rezafungin provisional CLSI clinical breakpoints and epidemiological cutoff values tested against a worldwide collection of contemporaneous invasive fungal isolates (2019 to 2020) by Carvalhaes CG, Klauer AL, Rhomberg PR, Pfaller MA, Castanheira, M in J. Clin. Microbiol. 2022; 60 (4) doi: 10.1128/jcm.02449-21

Evaluation of rezafungin provisional CLSI clinical breakpoints and epidemiological cutoff values tested against a worldwide collection of contemporaneous invasive fungal isolates (2019 to 2020) by Carvalhaes C, Klauer A, Rhomberg PR, Pfaller MA, Castanheira M in J. Clin. Microbiol. 2022; 60 (4), https://doi.org/10.1128/jcm.02449-21.

Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018-2020) by Sader, HS, Castanheira, M, Huband MD, Shortridge, D, Carvalhaes, CG, Mendes, RM in Eur. J. Clin. Microbiol. Infect. Dis. 2022; 41, 867-873.

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program. By Shortridge D, Streit JM, Mendes R, and Castanheira M published in Microbiol. Spectr. 2022; 10 (2),  e02712-21.

Antimicrobial Activity of Gepotidacin Against Recent Clinical Isolates of Escherichia coli Collected from Japan in 2019-2020. Lead author: SJ Ryan Arends. Japanese Association of Infectious Diseases (JAID) 22-23 April 2022.

Antimicrobial Activity of New Beta-Lactam/Beta-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa and Enterobacterales from Patients with Pneumonia in Intensive Care Units. Lead author: HS Sader presented at American Thoracic Society May 13-18, 2022, San Francisco, CA, USA

Antimicrobial Activity of Dalbavancin and Comparators against Gram-positive Bacteria Causing Bacteraemia in Patients with Skin and Skin Structure Infections (2017-2021). Lead author: HS Sader presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal

Antimicrobial Susceptibility of Organisms Isolated from Complicated UTI in Europe: Results from the SENTRY Antimicrobial Surveillance Program (2019-2021). Lead author: CG Carvalhaes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster # 1114

Lefamulin Activity against Bacterial Pathogens Typically Causing Pneumonia Collected from European Medical Centres in 2020 and 2021. Lead author: HS Sader presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1119

Cefiderocol In Vitro Activity against Molecularly Characterized Acinetobacter baumannii-calcoaceticus complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in Europe and Adjacent Regions (2020). Lead author: RE Mendes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1163

Prevalence of Carbapenemases and Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Among a Global Collection of Enterobacterales. Lead author: M Castanheira, presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #2164

Comparison Analysis of In vitro Activity of Cefiderocol and Comparator Agents against Molecularly Characterized Carbapenem-resistant Enterobacterales Clinical Isolates Causing Infections in Europe and Surrounding Regions (2020). Lead author: RE Mendes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1158

Activity of Cefiderocol and Comparators against US isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, including Carbapenem-Resistant Isolates from the SENTRY Antimicrobial Surveillance Program (2020-2021). Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1099

Activity of Cefiderocol and Comparators against US Enterobacterales, including Carbapenem-Resistant Isolates, from the SENTRY Antimicrobial Surveillance Program (2020-2021). Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #01091

Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific. Lead author: C Carvalhaes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1148

Performance of the VITEK 2 Advanced Expert System (AES) as a Rapid Tool for Reporting Antimicrobial Susceptibility Testing (AST) in Enterobacterales. Lead author: C Carvalhaes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1139

Activity of Meropenem Combined with the β-Lactamase Inhibitor Xeruborbactam and Comparator Agents Tested Against Challenging Gram-negative Organisms. Lead author: M Castanheira presented at European Congress of Clinical Microbiology and Infectious Diseaes (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #01593

Activity of Cefiderocol and Comparators against European Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus complex, and Stenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Program (2020-2021). Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1063

In Vitro Evaluation of Delafloxacin Activity Against Contemporary European Isolates from Community-Acquired Pneumonia and Lower Respiratory Tract Infections: Results from the SENTRY Antimicrobial Surveillance Program (2018-2021). Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #00563

Bloodstream Infections in Europe: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2019-2021). Lead author: HS Sader presented at European Congress of Clinical Microbiology and Infections Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #391

Oritavancin Activity Against Gram-positive Isolates Responsible for Intra-Abdominal Infections in Europe and Surrounding Regions During 2015-2019. Lead author: CG Carvalhaes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #466

Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa from Patients in ICU of US Medical Centres in 2021. Lead author: HS Sader, presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal

Endemicity of Pseudomonas aeruginosa Producing IMP-18 and/or VIM-2 Metallo-β-Lactamases from the High-Risk Clone ST111 in Central America. Lead author: LM Deshpande presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portgual
Poster #01136

In Vitro Activity of Gepotidacin and Comparators Against a Collection of E. coli and S. saprophyticus Urine Isolates Collected Worldwide During 2019-2021. Lead author: SJR Arends presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #01015

Activity of Meropenem-Vaborbactam and Comparators Against European Carbapenem-Resistant Enterobacterales Isolates Producing KPC Carbapenemase (2018-2020). Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #567

Epidemiology of Escherichia coli Surveillance Isolates Causing Urinary Tract Infections in Europe and In Vitro Activity of Gepotidacin (2019-2020). Lead author: RE Mendes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #01030

Antimicrobial Susceptibility of Enterobacterales Causing Infections in Intensive Care Unit Patients: The Role of New β-Lactamase Inhibitor Combinations. Lead author: CG Carvalhaes, presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal

Evaluation of Gepotidacin Activity when Combined with Select Antimicrobial Agents and Tested Against Bacterial Isolates Using Checkerboard Methodology. Lead author: SJR Arends presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #L0184

Activity of Cefiderocol and Comparators against European Enterobacterales including Carbapenem-Resistant Isolates. Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1050

Antimicrobial Activity of Aztreonam-avibactam and Comparator Agents against Ceftazidime-avibactam-resistant Enterobacterales (2019-2021). Lead author: HS Sader presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #381

Lefamulin Activity against Bacterial Pathogens Typically Causing Pneumonia Collected from European Medical Centres in 2020 and 2021. Lead author: HS Sader presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1128

Dalbavancin Activity against Bacterial Isolates from Pediatric Patients: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program for the United States and Europe (2019-2021). Lead author: HS Sader presented at St Jude/PIDS Pediatric Infectious Diseases Research Conference, March 3-5, 2022. Virtual conference

Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019-2020). by Sader HS, Mendes RE, Arends SJR, Carvalhaes CG and Castanheira M. published in Eur. J. Clin. Microbiol. Infect. Dis. 2022; 41 (3): 477-487

Comparative activity of newer beta-lactam/beta-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020. by Sader HS, Carvalhaes CG, Shortridge D and Castanheira M. published in Eur. J. Clin. Microbiol. Infect. Dis. 2022; 41 (2): 319-324

Correction: Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: Data from the SENTRY Antifungal Surveillance Program (2011-2019). by Pfaller MA, Carvalhaes CG, Rhomberg P, Messer SA and Castanheira M. published in J. Antibiot. (Tokyo). 2022; 75 (2): 123

Activity of the novel aminomethylcycline KBP-7072 and comparators against 1,057 geographically diverse recent clinical isolates from the SENTRY Surveillance Program, 2019. by Huband MD, Thompson JD, Gurung ND, Liu Q, Li L, Zhang J, Streit JM and Castanheira M. published in Antimicrob. Agents Chemother. 2022; 66 (1): e0139721

Activity of oritavancin against Gram-positive pathogens causing bloodstream infections in the United States over 10 Years: Focus on drug-resistant enterococcal subsets (2010-2019). by Carvalhaes CG, Sader HS, Streit JM, Castanheira M and Mendes RE. published in Antimicrob. Agents Chemother. 2022; 66 (2): e0166721

Elderly versus nonelderly patients with invasive fungal infections: species distribution and antifungal resistance, SENTRY Antifungal Surveillance Program 2017-2019. by Pfaller MA, Carvalhaes CG, DeVries S, Huband MD and Castanheira M. published in Diagn. Microbiol. Infect. Dis. 2022; 102 (4): 115627

Antimicrobial activity of high-dose cefepime-tazobactam (WCK 4282) against a large collection of gram-negative organisms collected worldwide in 2018 and 2019. by Sader HS, Carvalhaes CG, Mendes RE and Castanheira M. published in Int. J. Infect. Dis. 2022; 116: 306-312

Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019. by Pfaller MA, Huband MD, Shortridge D and Flamm RK. published in J. Glob. Antimicrob. Resist. 2021; 27: 337-351

Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates. by Castanheira M, Doyle TB, Collingsworth TD, Sader HS and Mendes RE. published in J. Antimicrob. Chemother. 2021; 76 (12): 3125-3134

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections. by Sader HS, Castanheira M, Duncan LR and Mendes RE. published in Int. J. Infect. Dis. 2021; 113: 279-281

Antimicrobial susceptibility of Gram-negative bacteria from intensive care unit and non-intensive care unit patients from United States hospitals (2018-2020). by Sader HS, Mendes RE, Streit JM, Carvalhaes CG and Castanheira M. published in Diagn. Microbiol. Infect. Dis. 2022; 102 (1): 115557

Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis, and Candida glabrata, Lead author: CG Carvalhaes presented at 10th Trends in Medical Mycology (TIMM10), October 8-11, Virtual and Abdereen, Scotland, UK.
Poster # 338

Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. by Castanheira M, Doyle TB, Deshpande LM, Mendes RE and Sader HS. published in Int. J. Antimicrob. Agents. 2021; 58 (5): 106439

Evaluation of the In Vitro Activity of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from the United States: Results from 10 Years of the AWARE Surveillance Program (2011-2020), Lead author: HS Sader. Presented at CHEST 2021 Annual Meeting, October 17-20, Virtual and Orlando, FL

Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Infective Endocarditis from the United States and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program, Lead author: HS Sader. Presented at CHEST 2021 Annual Meeting, October 17-20, Virtual and Orlando, FL
Poster #36440

Comparison of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Meropenem-Vaborbactam In Vitro Activities against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers in 2020 presented, Lead author: HS Sader. Presented at American Thoracic Society (ATS) 2021, May 14-19, Virtual Conference
Poster #8470